Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jul 20069:12 amRNSDirector/PDMR Shareholding
29th Jun 20069:37 amRNSEmployee Share Option Scheme
27th Jun 200610:11 amRNSGrant of US Patent
5th Jun 200610:14 amRNSHolding(s) in Company
10th May 20069:27 amRNSHolding(s) in Company
13th Apr 20063:25 pmRNSDirector/PDMR Shareholding
13th Apr 200612:47 pmRNSNew faceLAB Camera Product
10th Apr 20069:19 amRNSMajor Industry Awards Win
15th Mar 20067:01 amRNSInterim Results
3rd Mar 20069:42 amRNSAGM Statement-Amendment
28th Feb 20069:15 amRNSAGM Statement
8th Feb 20069:25 amRNSHolding(s) in Company
31st Jan 20069:30 amRNSHolding(s) in Company
25th Jan 20069:24 amRNSHolding(s) in Company
10th Jan 20069:18 amRNS1st Glaucoma Trial Completion
20th Dec 20053:46 pmRNSIssue of Equity
6th Dec 20059:41 amRNSHolding(s) in Company
1st Dec 20058:53 amRNSAdmission to AIM-Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.